In what was a decision that was four months ahead of schedule, the FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu. This is the first therapy targeted to treat unresectable or metastatic breast cancer expressing low levels of HER2, a brand-new category that was once part of the HER2-negative group.
Click here to read the entire article.